Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms.

Ibritumomab, an (90)Yttrium ((90)Y) labelled radioimmunoconjugate, is registered in Europe to treat follicular lymphomas. Its mode of action combines the selectivity of monoclonal antibodies with the efficiency of radiotherapy, making it a unique and useful therapeutic agent. This paper is for haemato-oncologists with a decent practice in lymphoma therapy, who have not yet used ibritumomab themselves. It summarizes clinical trials with radioimmunotherapy, indicating clinical situations where it may be specifically useful.
AuthorsWojciech Jurczak, Alicja Hubalewska-Dydejczyk, Agnieszka Giza, Anna Sowa-Staszczak, Bohdan Huszno, Aleksander B Skotnicki
JournalNuclear medicine review. Central & Eastern Europe (Nucl Med Rev Cent East Eur) Vol. 10 Issue 2 Pg. 110-5 ( 2007) ISSN: 1506-9680 [Print] Poland
PMID18228216 (Publication Type: Journal Article, Meta-Analysis, Review)
Chemical References
  • Antibodies, Monoclonal
  • Radiopharmaceuticals
  • ibritumomab tiuxetan
  • Algorithms
  • Antibodies, Monoclonal (therapeutic use)
  • Clinical Trials as Topic (trends)
  • Decision Support Systems, Clinical
  • Europe
  • Humans
  • Lymphoma (radiotherapy)
  • Radioimmunotherapy (trends)
  • Radiopharmaceuticals (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: